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a b s t r a c t
Background: More than 50% of new cases of lung cancer (LC) are diagnosed in elderly patients.
It is necessary to know correct treatment of these patients but there is a lack of evidence-
based data regarding this age group, leading to an undertreatment based on a supposed lack
of tolerance to radical treatments.
Aim: To evaluate the results of radiotherapy (RT) treatment in elderly patients with LC in our
institution and the relation between survival, toxicity and comorbidities.
Materials and methods: We retrospectively analyzed all patients over 70 years old with LC,
treated with RT with or without chemotherapy (CT), in the radiotherapy department of the
Instituto Português de Oncologia do Porto Francisco Gentil (IPOPFG), between January 2000
and December 2007.
Results: Three-year overall survival (OS) ratewas 33.8%.Median progression free survivalwas
18.1 months. For patients treated with exclusive radical radiotherapy the 3-year OS rate was
51.5% and for patients treated with sequential and concurrent CTRT, 3-year survival rates
were 44% and 25.4%, respectively. We did not ﬁnd a statistical relationship between the pres-
ence of comorbidities and survival. Toxicity presented by the patients was not inﬂuenced
by comorbidities and did not inﬂuence survival.Conclusion: Our results allow us to conclude that elderly patients are likely to beneﬁt from
radical treatments. Chemo-radiotherapy seems to increase survival but should be used care-
fully in old patients outside clinical trials. Comorbidities did not seem to inﬂuence survival
and toxicity of treatments, although larger studies are necessary to prove this.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
will rise, and it is necessary to know correct treatment of these. Background
ung cancer (LC) is the main cause of cancer death in western
ountries, and more than 50% of new cases are diagnosed in
lderly patients. In the last decade, the incidence and mor-
ality from LC have decreased among individuals aged 50
ears and younger but have increased among those aged 70
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years or older.1 Between 80% and 85% of LC are non-small-cell
lung cancers (NSCLC), and more than 50% of all patients with
NSCLC are older than 65 years.2 Because of the rapid aging of
populations, the proportion of LC diagnosed in elderly peoplepatients.
The main concern about aggressive treatment in the
elderly is that therapy results in excessive toxicity and poor
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Patients’ characteristics.
Characteristics Number of patients
Median age 74.5 (70–84)
Karnofsky performance status
50 1 (1.1%)
60 8 (8.9%)
70 8 (8.9%)
80 32 (35.6%)
90 38 (42.2%)
100 3 (3.3%)
Charlson score
0 45 (50%)
1 23 (25.6%)
2 15 (16.7%)
3 3 (3.3%)
4 1 (1.1%)
6 3 (3.3%)
Stage (NSCLC–TNM/AJCC)
IA 6 (7.2%)
IB 16 (19.3%)
IIA 2 (2.4%)
IIB 6 (7.2%)
IIIA 21 (25.3%)
IIIB 30 (36.2%)
IV 2 (2.4%)
Stage (SCLC)
Limited 5 (71.4%)
Extensive 2 (28.6%)
Histology
Squamous cell 36 (40%)
Adenocarcinoma 37 (41.1%)
Small cell carcinoma 7 (7.8%)46 reports of practical oncology a
outcome. However, age itself should not be used as a crite-
rion for the choice of a treatment modality. A comprehensive
geriatric assessment is mandatory to evaluate functional sta-
tus, comorbidities, mental status, psychological state, social
support, nutritional status, polypharmacy and geriatric condi-
tions, in order to improvepatients’ conditionbefore treatment.
There is a lack of evidence-based data regarding the appro-
priate treatment of the elderly, since they have generally been
excluded from prospective trials. This lack of information is
especially relevant in the ﬁeld of radiotherapy (RT), and has
led to an undertreatment of patients based on a supposed lack
of tolerance to radical treatments.
Age does not appear to have an inﬂuence on the frequency
and severity of acute and late side-effects, so it is not a suf-
ﬁcient reason to exclude patients from curative radiotherapy
when it is indicated, either in NSCLC or small-cell lung cancer
(SCLC).3,4
Elderly patientswhoparticipated in Phase III trials for stage
III NSCLC were likely to gain a survival advantage from RT and
chemotherapy (CT) compared with RT alone, although, as in
the case of younger patients, there was an additional toxicity
with this therapy modality.5
2. Aim
In this study we aimed to evaluate the global survival, progres-
sion free survival and acute toxicity of elderly patients treated
with RT for LC (both NSCLC and SCLC) in our institution. We
also studied the relation between survival and comorbidities
presented by the patients, in order to investigate if the progno-
sis differed in patients with signiﬁcant comorbidities, to adopt
a different attitude towards their management if indicated.
3. Materials and methods
Even though the deﬁnition of the elderly remains debatable,
we chose the age of 70 years as aminimum level.We retrospec-
tively analyzed all patients over 70 years old with LC, treated
with RT with or without CT, in the radiotherapy department of
the Instituto Português de Oncologia do Porto Francisco Gentil
(IPOPFG), between January 2000 and December 2007. Medical
records were reviewed and patients’ comorbidities were clas-
siﬁed according to the Charlson Score (Appendix A). Acute and
late toxicities were classiﬁed according to the Common Toxi-
city Criteria, version 2.0. Patients who had been treated with
RT for distant metastases were excluded.
Patients were treated with a 3D conformal plan to receive a
total dose of 60–70Gy with 2Gy daily fractions in the cases
with curative intent and a total dose of 40Gy with 2.5Gy
daily fractions for palliative intent. Energies used were 6MV
or 15MV, or a combination of both. Chemotherapy schemes
consisted of platinum associated with etoposide, gemcitabine
or paclitaxel.Data were analyzed using SPSS software version 17.0, over-
all survival (OS) and progression free survival (DFS) were
calculated using the Kaplan-Meier method, and the log-rank
test was used for differences between curves.Undifferentiated large cell 4 (4.4%)
Mixed histology 6 (6.7%)
4. Results
From January 2000 to December 2007, 90 patients over 70 years
old received treatmentwith RT for LC at IPOPFG. Patients’ char-
acteristics are summarized in Table 1.
The median age was 74.5 years (range 70–84) and most
patients presented a Karnofsky performance status of 80% or
more.
Half of the patients had a Charlson score of 0 (no signiﬁ-
cant comorbidities), 25.6% and 16.7% had a score of 1 and 2,
respectively, and 7 patients had a score≥3. Comorbidities pre-
sented by the patients are summarized in Tables 1 and 2. The
most frequent comorbidities presented by the patients were
chronic pulmonary disease (17.8%), diabetes (16.7%), other
tumors (12.2%) and ulcer disease (12.2%).
Stages IIIA and IIIB were the most frequent in NSCLC
(61.5%), and 71.4% of SCLC were staged as limited disease.
Adenocarcinoma and squamous cell carcinoma represented
41.1% and 40% of the NSCLC histologies, respectively.
Forty-eight patients (53.3%) were submitted to sequen-
tial chemo-radiotherapy (CTRT) and 10 patients (11.1%) were
treated with concurrent CTRT. Exclusive radiotherapy was
used in 27 patients, 17 with radical intent (18.9%) and 10 with
palliative intent (11.1%). Five patients (5.6%) were submitted
to surgery and adjuvant radiotherapy. Two patients were sub-
mitted to brachytherapy, one after concurrent CTRT and the
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Table 2 – Patients’ comorbidities.
Comorbidities Number of patients (%)
Chronic pulmonary disease 16 (17.8%)
Diabetes 15 (16.7%)
Other tumor 11 (12.2%)
Ulcer disease 4 (4.4%)
Congestive heart failure 3 (3.3%)
Myocardial infarct 3 (3.3%)
Cerebrovascular disease 2 (2.2%)
Metastatic solid malignancy 2 (2.2%)
Peripheral vascular disease 1 (1.1%)
Diabetes with end organ damage 1 (1.1%)
Dementia 1 (1.1%)
Moderate renal disease 1 (1.1%)
Leukemia 1 (1.1%)
Moderate liver disease 1 (1.1%)
Table 3 – Patients’ treatments.
Treatment Number of patients (%)
Sequential chemo-radiotherapy 48 (53.3%)
Concurrent chemo-radiotherapy 10 (11.1%)
Exclusive radical radiotherapy 17 (18.9%)
Post-surgery radiotherapy 5 (5.6%)
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eExclusive palliative radiotherapy 10 (11.1%)
Brachytherapy (after CTRT) 2 (2.2%)
Total 90
thers after sequential CTRT. Patients’ treatments are sum-
arized in Table 3.
The toxicities presented by the patients were mostly grade
and II, and 2 cases of grade III toxicity were registered, one
astro-intestinal (esophageal) and the other hematological
oxicity (leukopenia), which means a 2.2% grade III toxicity.
he patient that presented with grade III esophageal toxic-
ty had a Charlson score of 2, and the patient with grade III
ematological toxicity had a Charlson score of 0; both were
ubmitted to concurrent CTRT.
Results of curative radiotherapy are summarized in Table 4.
edian overall survival (OS) for all patientswas 29months and
he 3-year OS rate was 33.8%. Median progression free survival
or all patients was 18.1 months. For patients treated with
xclusive radical radiotherapy, median OS was 38.8 months
Table 4 – Treatment response after curative radiotherapy.
Treatment Number of patients (n=75)
Sequential chemo-radiotherapy 48
Partial response 6 (12.5%)
Complete response 2 (4.2%)
Stable disease 25 (52.1%)
Progression 14 (29.2%)
Unknown 1 (2.1%)
Concurrent chemo-radiotherapy 10
Partial response 2 (20%)
Complete response 1 (10%)
Stable disease 6 (60%)
Progression 1 (10%)
Exclusive radical radiotherapy 17
Partial response 4 (23.5%)
Stable disease 11 (64.7%)
Progression 2 (11.8%)Fig. 1 – Comorbidities and survival.
and the 3-year OS rate was 51.5%. For patients treated with
sequential and concurrent CTRT, median OS and 3-year sur-
vival rates were 28.6 and 15.3 months, and 44% and 25.4%,
respectively.
We did not ﬁnd a statistical relationship between the pres-
ence of comorbidities and survival, as shown in Fig. 1 (we
divided patients in two groups, one with Charlson score 0 (45
patients) and the other with Charlson score ≥1 (45 patients)).
In our analysis, the toxicity presented by the patients was
also not inﬂuenced by comorbidities, and did not inﬂuence
survival.
5. Discussion
Our study analyses one group of elderly patients who were
submitted to thoracic RT with or without CT. As a retrospec-
tive study, it presents a selection bias, and it is important to
explain the criteria usually considered in our institution when
deciding on the treatment strategy for this group of patients.
Patients with stage IV or large tumors, signiﬁcant comorbidi-
ties or Karnofsky performance status <70% are submitted to
thoracic radiotherapy with palliative intent (10 patients in this
study). The remaining cases are individually evaluated for
thoracic radiotherapy with radical intent; patients with sig-
niﬁcant comorbidities that are not suitable for chemotherapy
are submitted to RT alone, while the others are submitted to
CTRT.
There are few studies about treatment of LC in this age
group. Pignon et al. reviewed 1208 patients treated with tho-
racic RT, comparing the toxicities observed in 6 different age
groups and found no difference in the incidence of nau-
sea, dyspnoea, esophagitis, asthenia and performance status,
although weight loss was signiﬁcantly higher in the oldest
group (p=0.002).3Aprospective studywas done by Schild et al. to evaluate the
value of combined CTRT in the elderly with stage III NSCLC.
They studied 166 patients over 65 years old, and the results
showed a better OS in the group treated with CTRT (p=0.05),
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Table 5 – Survival after curative radiotherapy.
Treatment Median
progression free
survival (months)
Median overall
survival (months)
3-year overall
survival
r
aged 75 and over: safety, effectiveness and possible impact on
survival. Lung Cancer 2000;28(April (1)):43–50.All patients (n=75) 18.1
Exclusive radical RT (n=17) 20.0
Concurrent CTRT (n=10) 8.0
Sequential CTRT (n=48) 16.6
in spite of a signiﬁcantly higher incidence of grade III acute
toxicity (p<0.01).6
The low toxicity presented by our patients was probably
due to the fact that few patients had been submitted to con-
current CTRT as a result of our strict selection criteria.
Lonardi et al. have reviewed 48 patients over 75 years old
treated with RT for NSCLC stages IIIA and IIIB, and concluded
that there was a signiﬁcant increase in overall survival for
patients treatedwith doses higher then 50Gy,when compared
with patients treated with lower doses.7
In this study, all patients treated with radical intent were
submitted to radiation doses higher than 50Gy.
A phase III study of the North Central Cancer Treat-
ment Group (NCCTG) compared the results of treatment with
combined RTCT, conventionally fractionated RT and hyper-
fractionated RT, and examined the relationship between age
and outcome of treatments. The results showed that survival
was not signiﬁcantly worse in older individuals, although tox-
icity was higher in this group.8
The available studies show that combined CTRT is possi-
ble in this age group, with better results as compared with RT
alone.
In our study, when comparing survival for the different
treatment groups (Table 5), we found a better survival in the
exclusive radiotherapy group (with radical intent), compared
with the two groups treated with CTRT. The number of
patients in this study does not allow us to conclude that
RT alone is better than CTRT, but we can say that RT in
radical doses was well tolerated by our old patients with
comorbidities.
6. Conclusion
Our results were similar to those described in the literature
for younger aged groups, which allows us to conclude that
elderly patients are likely to beneﬁt from radical treatments.
The sequential or concurrent chemotherapy seems to increase
survival but should be carefully used in old patients outside
clinical trials. In this study, concomitant CTRT seemed to deliver
worse survival, although it may be due to the small size of the
sample.
Appendix A. Appendix A – Charlson scoreCondition Assigned weight
Myocardial infarction 1
Congestive heart failure 129 33.8%
38.8 51.5%
15.3 25.4%
28.6 44%
Appendix A Continued
Condition Assigned weight
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Chronic pulmonary disease 1
Connective tissue disease 1
Ulcer disease 1
Liver disease mild 1
Diabetes 1
Hemiplegia 2
Renal disease moderate or severe 2
Diabetes with end organ damage 2
Any malignancy 2
Leukemia 2
Malignant lymphoma 2
Liver disease. Moderate or severe 3
Metastatic solid malignancy 6
AIDS 6
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